Previous studies have implicated FGF2 in the obesity–cancer axis, as VAT levels of FGF2 were positively correlated with the capacity of VAT to stimulate mammary and skin epithelial cell growth, and circulating FGF2 levels were associated with overall adipose tissue mass in humans [15]. This evidence concerns the gene FGF2 and cancer.